ArticleFrontiers in oncology2024
Vitronectin promotes proliferation and metastasis of cervical cancer cells via the epithelial-mesenchymal transition.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Proteomic Analysis of Extracellular Vesicles Reveals Vitronectin and Laminin Subunit Alpha-3 as Candidate Biomarkers for Gastric Cancer.Gut and liver · 2026Article
- Extracellular Vesicle Proteomics in Gastric Cancer: Moving Beyond Early Detection.Gut and liver · 2026Article
- Vitronectin Enrichment in Prostate Cancer Liver Metastases Promotes Adhesion and Survival.Cancer research communications · 2026Article
- Lipid nanoparticles as active biointerfaces: From membrane interaction to systemic dysregulation.Acta pharmaceutica Sinica. B · 2026Review
- Angiogenic Prognostic Signature for Stratification in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Investigating the Cellular Responses to Combined Nisin and Urolithin B Treatment (7:3) in HKB-11 Lymphoma Cells.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vitronectin (VTN) is a multifunctional glycoprotein in blood and the extracellular, which could be an effective biomarker for many cancers. However, its role in cervical cancer is under investigated. In this study, we aimed to determine the molecular function of VTN and its potential mechanism in cervical cancer (CC). Materials and methods: Up- and down-regulated VTN expression was determined in Hela and C33A cells. Reverse transcription, qRT-PCR, and Western blotting test were performed to identify VTN mRNA and protein levels, separately. CCK-8 assay and colony formation assay were carried out to evaluate proliferation abilities of CC cells. A scratch test and a transwell chamber assay were performed to determine cell migration and invasion ability. Expression levels of epithelial-mesenchymal transition (EMT)-related proteins were measured by Western blotting. Results: Cell models with up- and down-regulated VTN expression in Hela and C33A cells were successfully established, as confirmed by Western blotting and qPCR. CCK-8 and colony formation assays demonstrated that VTN overexpression significantly enhanced the proliferation of both Hela and C33A cells. Wound healing and Transwell migration assays further indicated that VTN overexpression markedly promoted the migratory and invasive capabilities of these cells. Moreover, Western blotting analysis revealed that VTN overexpression led to a decrease in ZO-1 and E-cadherin protein levels and an increase in β-catenin and N-cadherin levels, whereas VTN knockdown yielded the opposite effect. These findings suggest that VTN promotes cervical cancer cell malignancy through epithelial-mesenchymal transition (EMT). Conclusion: VTN plays a tumor-promoting role in CC by promoting the EMT of cervical cancer cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.